唐氏综合征中逆转录体复合体系统失调
该研究检测唐氏综合征患者尸脑组织和成纤维细胞中逆转录体复合体蛋白,发现识别核心蛋白显著降低,且与可溶性Aβ1-40和1-42水平呈负相关;结论认为逆转录体失调是唐氏综合征AD样病理和认知下降的早期事件,可能成为治疗靶点。
要点
- 唐氏综合征患者成纤维细胞及年轻和年老脑组织中逆转录体识别核心蛋白显著降低。
- 海马和皮层中识别核心蛋白与可溶性Aβ1-40、1-42水平呈显著负相关。
- 逆转录体复合体失调可能是唐氏综合征AD样病理的早期事件和潜在治疗靶点。
核心结论
- 逆转录体复合体系统失调是唐氏综合征中AD样病理和认知下降发展的早期事件,可能成为新的治疗靶点。
研究设计与样本
- 研究采用唐氏综合征患者和健康对照的尸脑组织及成纤维细胞,通过Western blot和RT-qPCR检测逆转录体复合体蛋白组分。
主要发现
- 唐氏综合征成纤维细胞中逆转录体识别核心蛋白显著降低。
- 年轻(15-40岁)和年老(40-65岁)唐氏综合征患者的海马和皮层中逆转录体识别核心蛋白均显著低于对照。
- 海马组织中识别核心蛋白与可溶性Aβ1-40和1-42水平呈显著负相关(n=33,Spearman=-0.59至-0.38,VPS35、VPS26、VPS29和VPS26B的p≤0.03)。
- 皮层组织中识别核心蛋白与可溶性Aβ1-40和1-42水平呈显著负相关(n=57,Spearman=-0.46至-0.27,VPS35、VPS26和VPS29的p≤0.04)。
临床怎么用
- 逆转录体复合体系统可作为唐氏综合征中AD样病理的早期生物标志物和潜在治疗靶点进行进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Most of the patients with Down syndrome (DS) develop Alzheimer's disease (AD) neuropathology by age 40. Although this increased susceptibility to AD in DS is thought to be primarily due to triplication of the amyloid precursor protein located on chromosome 21, the precise molecular mechanisms are not well understood. Recent evidence has implicated defective protein sorting and trafficking secondary to deficiencies in retromer complex proteins in AD pathogenesis. Thus, the objective of the present study is to assess the retromer complex system in DS. METHODS: Human postmortem brain tissue and fibroblasts from subjects with DS and healthy controls were examined for the various retromer protein components using Western blot analysis and reverse transcription quantitative polymerase chain reaction (RT-qPCR). RESULTS: Retromer recognition core proteins were significantly decreased in DS fibroblasts, and in both the hippocampi and cortices of young (age 15-40 years old) and aged (40-65 years old) subjects with DS compared with controls. Correlation analyses showed a significant inverse relationship between recognition core proteins and levels of soluble forms of Aβ 1-40 and 1-42 in both hippocampus (n = 33, Spearman = -0.59 to -0.38, p ≤ 0.03 for VPS35, VPS26, VPS29, and VPS26B) and cortex tissue (n = 57, Spearman = -0.46 to -0.27, p ≤ 0.04 for VPS35, VPS26, and VPS29) of the same patients. INTERPRETATION: We conclude that dysregulation of the retromer complex system is an early event in the development of the AD-like pathology and cognitive decline in DS, and for this reason the system could represent a novel potential therapeutic target for DS. ANN NEUROL 2020 ANN NEUROL 2020;88:137-147.
引用
- Curtis ME, Yu D, Praticò D, et al. Dysregulation of the Retromer Complex System in Down Syndrome. Ann Neurol. 2020. PMID: 32320094. doi:10.1002/ana.25752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。